Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Solid Tumor 1Small Cell Lung Carcinoma 1Neoplasms 1Nasopharyngeal Carcinoma 1Disease Progression 1Breast Neoplasms 1

Interventions

toripalimab 5Cisplatin 5pembrolizumab 3Radiotherapy, Intensity-Modulated 3Heavy Ion Radiotherapy 3Gemcitabine 3anlotinib 2spartalizumab 1nedaplatin 1icotinib 1fludarabine phosphate 1fludarabine 1famitinib 1donafenib 1Vorinostat 1TP protocol 1Sodium Chloride 1SHR-1701 1Quality of Life 1Paclitaxel 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Interleukin-2 1Immunotherapy, Adoptive 1Gefitinib 1Cyclophosphamide 1Cetuximab 1Celecoxib 1Bevacizumab 1Adjuvants, Pharmaceutic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Nasopharyngeal Carcinoma × famitinib × Clear all
NCT05020925 2021-08-25

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Unknown
30 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡